Article info
PDFTherapeutic Intervention
Management of Glucocorticoid-Induced Osteoporosis – for Neurologists
Citation
Management of Glucocorticoid-Induced Osteoporosis – for Neurologists
Publication history
- First published October 1, 2004.
Online issue publication
February 01, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2004 BMJ
Other content recommended for you
- Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study
- Glucocorticoid-induced osteoporosis
- Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density
- Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids
- What is osteoporosis?
- Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study
- The pathogenesis, diagnosis, investigation and management of osteoporosis
- From bone biology to clinical outcome: state of the art and future perspectives
- Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study
- Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study